Worth reading
69In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Deterioration
Direction inferred from the company’s description.Scale
-7496
¥ million (change in ordinary profit)Wording
Definitive
How definitive the wording is.Revised forecast
Fiscal year ending December 2025 · Full yearNet Sales—→—million
—
Operating profit—→—million
—
Ordinary income—→—million
—
Profit attributable to owners of the parent—→—million
—
Net income per share—→—yen
—
The bar length represents the relative magnitude of change, based on the item that changed the most in this document.
Reason for the revision
前期にGNI USAが保有するGyre Therapeutics, Inc.の普通株式による債権返済を受け、貸倒引当金の戻入益約6,021百万円を計上した反動に加え、当期に自社株価予約取引に係る一過性損失630百万円を計上したため。
Details and amount of extraordinary loss
自社株価予約取引に係る一過性損失630百万円。前期には貸倒引当金の戻入益約6,021百万円を計上。
Previous-period results売上収益24百万円、営業利益△657百万円、経常利益5,903百万円、当期純利益5,903百万円、１株当たり当期純利益118円06銭
Consolidated / non-consolidatedNon-consolidated
| Item | Details |
|---|---|
| Net Sales | △2 |
| Operating profit | △17 |
| Ordinary income | △7,496 |
| Profit attributable to owners of the parent | △7,238 |
| Net income per share | △143円50銭 |
| Fiscal Period Covered | Fiscal year ending December 2025 |
| Period Covered | Full year |
| Previous-period results | 売上収益24百万円、営業利益△657百万円、経常利益5,903百万円、当期純利益5,903百万円、１株当たり当期純利益118円06銭 |
| Reason for the revision | 前期にGNI USAが保有するGyre Therapeutics, Inc.の普通株式による債権返済を受け、貸倒引当金の戻入益約6,021百万円を計上した反動に加え、当期に自社株価予約取引に係る一過性損失630百万円を計上したため。 |
| Details and amount of extraordinary loss | 自社株価予約取引に係る一過性損失630百万円。前期には貸倒引当金の戻入益約6,021百万円を計上。 |
| Consolidated / non-consolidated | Non-consolidated |
Items this document does not state (2)
Publication date of previous forecastDividend forecast revision
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.前期に計上した貸倒引当金の戻入益約6,021百万円の反動に加え、当期に自社株価予約取引に係る一過性損失630百万円を計上したため。
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.